Table 2.
Six month post‐IASD features according to HFH status
| No HFH (n = 45) | HFH (n = 19) | P value | |
|---|---|---|---|
| Body mass index (kg/m2) | 32 ± 1 | 34 ± 2 | 0.28 |
| NT‐proBNP (pg/mL) | 332 (180–821) | 609 (304–2022) | 0.09 |
| eGFR (mL/min/1.73 m2) | 63 ± 3 | 53 ± 4 | 0.08 |
| 6MWD (m) | 375 ± 14 | 312 ± 23 | 0.03 |
| Peak exercise workload (W) | 52 ± 3 | 41 ± 5 | 0.048 |
| Echocardiography | |||
| LVEF (%) | 50 ± 1 | 47 ± 2 | 0.19 |
| LAVI (mL/m2) | 35 ± 4 | 35 ± 4 | 0.99 |
| RAVI (mL/m2) | 40 ± 4 | 40 ± 3 | 0.99 |
| TAPSE (cm) | 2.0 ± 0.1 | 1.9 ± 0.1 | 0.21 |
| Resting haemodynamics | |||
| RA pressure (mmHg) | 10 ± 1 | 12 ± 1 | 0.12 |
| PAm pressure (mmHg) | 24 ± 1 | 25 ± 1 | 0.49 |
| PCWP (mmHg) | 16 ± 1 | 18 ± 1 | 0.24 |
| Cardiac index (L/min/m2) | 3.4 ± 0.1 | 3.2 ± 0.2 | 0.37 |
6MWD, 6 min walk distance; eGFR, estimated glomerular filtration rate; HFH, heart failure hospitalization; LAVI, left atrial volume index; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide; PAm, mean pulmonary artery; PCWP, pulmonary capillary wedge pressure; post‐IASD, post‐interatrial shunt device; RA, right atrial; RAVI, right atrial volume index; TAPSE, tricuspid annular plane systolic excursion.